NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT00749450,Combination Chemotherapy After Surgery in Treating Patients With High-Risk Stage II or Stage III Colorectal Cancer,https://clinicaltrials.gov/study/NCT00749450,,COMPLETED,"RATIONALE: Drugs used in chemotherapy, such as oxaliplatin, fluorouracil, and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known which combination chemotherapy regimen is more effective in treating patients who have undergone surgery for high-risk colorectal cancer.

PURPOSE: This randomized phase III trial is studying chemotherapy given after surgery in treating patients with high-risk stage II or stage III colorectal cancer.",NO,Colorectal Cancer,DRUG: capecitabine|DRUG: fluorouracil|DRUG: oxaliplatin,"3-year disease-free survival, 3 years","Overall survival, assessed during 5 year recruitment period and maximum 7 year follow up period|Cost-effectiveness, assessed during 5 year recruitment period|Toxicity according to NCI CTCAE Version 3.0, assessed during 5 year recruitment period|Quality of life as assessed by EORTC QLQ-C30, EORTC QLQ-CR29, EQ-5D, and GOG Ntx4, assessed during 5 year recruitment period",,"Cancer Research UK, Glasgow",,ALL,"ADULT, OLDER_ADULT",PHASE3,6088,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,CDR0000613042|CRUK-SCOT|ISRCTN59757862|EudraCT 2007-003957-10|EU-20874|SCOT-2007-01,2008-03,2017-11,,2008-09-09,,2018-07-27,"Beatson West of Scotland Cancer Centre, Glasgow, Scotland, G12 0YN, United Kingdom",
